BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Baxfendy (Baxdrostat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Baxfendy (Baxdrostat)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07222917-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Baxfendy (Baxdrostat): Phase 2 readout est. (NCT07222917)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 2\, Hypertension.\nStudy: A Phase
  IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Bax
 drostat Compared With Baxdrostat on Albuminuria in Participants With Chron
 ic Kidney Disease and High Blood Pressure.\nEstimated primary completion: 
 10 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bax
 drostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07222917
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007793-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07007793)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3.\nStudy: Parent Study: A Study 
 to Assess Efficacy and Safety of Baxdrostat in Participants With Primary A
 ldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA
  Main Study.\nEstimated primary completion: 27 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07007793
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686120-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07686120)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participant
 s With Uncontrolled Hypertension.\nEstimated primary completion: 9 Februar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076861
 20
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06268873)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Study to Investigate the Efficacy and Safety of Baxdrostat in Combina
 tion With Dapagliflozin on CKD Progression in Participants With CKD and Hi
 gh Blood Pressure.\nEstimated primary completion: 24 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06268873
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07800858-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Baxfendy (Baxdrostat): Phase na readout est. (NCT07800858)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase na.\nStudy: Baxdrostat and Molecu
 lar Imaging of Adrenal Cytoreduction in Primary Aldosteronism\nEstimated p
 rimary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/baxdrostat#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07800858
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655362-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07655362)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3.\nStudy: Baxdrostat and Ventric
 ular Remodeling\nEstimated primary completion: 30 June 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07655362
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06677060)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Heart Failure.\nStudy: Phase 
 III Study Investigating Heart Failure and Cardiovascular Death With Baxdro
 stat in Combination With Dapagliflozin\nEstimated primary completion: 17 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdros
 tat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06677060
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-525@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06742723)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Renal Outcomes and Cardiovascular Mortality Study to Investigate the 
 Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Par
 ticipants With Chronic Kidney Disease and High Blood Pressure\nEstimated p
 rimary completion: 18 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/baxdrostat#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
